Publications

Nature medicine

Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial.

01-12-2020

Key

Journal of pharmaceutical and biomedical analysis

A multiplex UPLC-MS/MS method for the quantification of three PD-L1 checkpoint inhibitors, atezolizumab, avelumab, and durvalumab, in human serum.

15-06-2024

Nature communications

Spatial relationships in the urothelial and head and neck tumor microenvironment predict response to combination immune checkpoint inhibitors.

21-03-2024

Annals of oncology : official journal of the European Society for Medical Oncology

ESMO Clinical Practice Guideline interim update on first-line therapy in advanced urothelial carcinoma.

13-03-2024

The New England journal of medicine

Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer.

07-03-2024

European urology

Management of Lymph Node-positive Penile Cancer: A Systematic Review.

01-03-2024

European urology

Health-related Quality of Life in Patients with Previously Treated Advanced Urothelial Carcinoma from EV-301: A Phase 3 Trial of Enfortumab Vedotin Versus Chemotherapy.

27-02-2024

Nature communications

Gene-expression-based T-Cell-to-Stroma Enrichment (TSE) score predicts response to immune checkpoint inhibitors in urothelial cancer.

14-02-2024

British journal of cancer

Urine-derived bladder cancer organoids (urinoids) as a tool for cancer longitudinal response monitoring and therapy adaptation.

01-02-2024

The Lancet. Oncology

Accelerating neoadjuvant chemotherapy for muscle-invasive bladder cancer.

01-02-2024

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Reply to Y.-N. Feng et al.

10-01-2024

International journal of radiation oncology, biology, physics

Disease-Free Survival of Patients With Muscle-Invasive Bladder Cancer Treated With Radical Cystectomy Versus Bladder-Preserving Therapy: A Nationwide Study.

01-01-2024

Nature medicine

Author Correction: High- or low-dose preoperative ipilimumab plus nivolumab in stage III urothelial cancer: the phase 1B NABUCCO trial.

01-01-2024

Nature reviews. Urology

Turning up the heat: CTLA4 blockade in urothelial cancer.

01-01-2024

Nature medicine

Publisher Correction: Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial.

01-12-2023

The New England journal of medicine

Nivolumab plus Gemcitabine-Cisplatin in Advanced Urothelial Carcinoma.

09-11-2023

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Atezolizumab With or Without Radiotherapy for Advanced Squamous Cell Carcinoma of the Penis (The PERICLES Study): A Phase II Trial.

01-11-2023

Frontiers in immunology

The bladder cancer immune micro-environment in the context of response to immune checkpoint inhibition.

20-09-2023

Frontiers in oncology

Induction therapy with ipilimumab and nivolumab followed by consolidative chemoradiation as organ-sparing treatment in urothelial bladder cancer: study protocol of the INDIBLADE trial.

15-09-2023

International journal of radiation oncology, biology, physics

A Prospective Study of Chemoradiotherapy as Primary Treatment in Patients With Locoregionally Advanced Penile Carcinoma.

01-09-2023

Current opinion in urology

Recent developments in perioperative combination therapy in muscle-invasive bladder cancer.

01-09-2023

BJU international

Prognostic impact of variant histologies in urothelial bladder cancer treated with radical cystectomy.

01-08-2023

European urology

Corrigendum to "Assessment of Predictive Genomic Biomarkers for Response to Cisplatin-based Neoadjuvant Chemotherapy in Bladder Cancer" [Eur Urol 2023;83:313-17].

01-06-2023

European urology

European Association of Urology-American Society of Clinical Oncology Collaborative Guideline on Penile Cancer: 2023 Update.

01-06-2023

Cancer medicine

Phase II study (KAMELEON) of single-agent T-DM1 in patients with HER2-positive advanced urothelial bladder cancer or pancreatic cancer/cholangiocarcinoma.

01-06-2023

European urology

Assessment of Predictive Genomic Biomarkers for Response to Cisplatin-based Neoadjuvant Chemotherapy in Bladder Cancer.

01-04-2023

Nature medicine

High- or low-dose preoperative ipilimumab plus nivolumab in stage III urothelial cancer: the phase 1B NABUCCO trial.

01-03-2023

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

FORT-1: Phase II/III Study of Rogaratinib Versus Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Selected Based on FGFR1/3 mRNA Expression.

20-01-2023

European urology

Re: Neoadjuvant PD-L1 plus CTLA-4 Blockade in Patients with Cisplatin-ineligible Operable High-risk Urothelial Carcinoma.

01-01-2023

International journal of cancer

Survival after neoadjuvant/induction combination immunotherapy vs combination platinum-based chemotherapy for locally advanced (Stage III) urothelial cancer.

01-12-2022

International journal of cancer

Reply to: Comments on "Neoadjuvant/induction combination immunotherapy vs combination platinum-based chemotherapy for locally advanced (Stage III) urothelial cancer".

15-11-2022

Cancer discovery

Escherichia coli-Specific CXCL13-Producing TFH Are Associated with Clinical Efficacy of Neoadjuvant PD-1 Blockade against Muscle-Invasive Bladder Cancer.

05-10-2022

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology

Disease outcome and associated factors after definitive platinum based chemoradiotherapy for advanced stage HPV-negative head and neck cancer.

01-10-2022

European urology

Final Results of Neoadjuvant Atezolizumab in Cisplatin-ineligible Patients with Muscle-invasive Urothelial Cancer of the Bladder.

01-08-2022

Urologic oncology

Corrigendum to: Mechanistic target of rapamycin (mTOR) protein expression in the tumor and its microenvironment correlates with more aggressive pathology at cystectomy.

01-07-2022

British journal of clinical pharmacology

Exposure-response relationship of ramucirumab in RANGE, a randomized phase III trial in advanced urothelial carcinoma refractory to platinum therapy.

01-07-2022

European urology focus

Overall Survival of Patients Receiving Cisplatin or Carboplatin for Primary Metastatic Urothelial Carcinoma of the Bladder: A Contemporary Dutch Nationwide Cohort Study.

01-07-2022

Nature communications

Predictive biomarkers for survival benefit with ramucirumab in urothelial cancer in the RANGE trial.

06-04-2022

Clinical genitourinary cancer

A Serendipitous Preoperative Trial of Combined Ipilimumab Plus Nivolumab for Localized Prostate Cancer.

01-04-2022

European urology

Comprehensive Molecular Characterization Reveals Genomic and Transcriptomic Subtypes of Metastatic Urothelial Carcinoma.

01-04-2022

Urologic oncology

Prognostic markers in invasive bladder cancer: FGFR3 mutation status versus P53 and KI-67 expression: a multi-center, multi-laboratory analysis in 1058 radical cystectomy patients.

01-03-2022

Annals of oncology : official journal of the European Society for Medical Oncology

Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.

01-03-2022

Frontiers in immunology

Molecular, Immunological, and Clinical Features Associated With Lymphoid Neogenesis in Muscle Invasive Bladder Cancer.

12-02-2022

Frontiers in immunology

The Tumor Immune Landscape and Architecture of Tertiary Lymphoid Structures in Urothelial Cancer.

07-01-2022

European urology focus

Partial Response and Stable Disease Correlate with Positive Outcomes in Atezolizumab-treated Patients with Advanced Urinary Tract Carcinoma.

01-09-2021

The Journal of urology

Safety and Efficacy of Atezolizumab in Understudied Populations with Pretreated Urinary Tract Carcinoma: Subgroup Analyses of the SAUL Study in Real-World Practice.

01-08-2021

European urology

Atezolizumab Versus Chemotherapy in Patients with Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: A Long-term Overall Survival and Safety Update from the Phase 3 IMvigor211 Clinical Trial.

01-07-2021

Scientific reports

A kinome-centered CRISPR-Cas9 screen identifies activated BRAF to modulate enzalutamide resistance with potential therapeutic implications in BRAF-mutated prostate cancer.

01-07-2021

The Lancet. Oncology

Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial.

01-06-2021

European urology oncology

Toxicity and Surgical Complication Rates of Neoadjuvant Atezolizumab in Patients with Muscle-invasive Bladder Cancer Undergoing Radical Cystectomy: Updated Safety Results from the ABACUS Trial.

01-06-2021